Antoni Garcia-Guinon
Overview
Explore the profile of Antoni Garcia-Guinon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
182
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garcia-Guinon A, Charry P, Jimenez M, Sarra J, Delgado I, Segura de la Torre L, et al.
Ann Hematol
. 2025 Feb;
PMID: 39954075
Carfilzomib, lenalidomide and dexamethasone (KRd) is still a widely used treatment option for patients with relapsed / refractory multiple myeloma (RRMM). However, there is limited real-world evidence. Here we evaluated...
2.
Ribera J, Morgades M, Garcia-Calduch O, Sirvent M, Buendia B, Cervera M, et al.
Haematologica
. 2023 Aug;
109(2):543-552.
PMID: 37560813
High dose-intensive or infusional intermediate-dose immunochemotherapy is highly effective treatment for Burkitt lymphoma irrespective of human immunodeficiency virus (HIV) infection. However, toxicities of these regimens are relevant, especially in older...
3.
Rios-Tamayo R, Soler J, Garcia-Sanchez R, Persona E, Arnao M, Garcia-Guinon A, et al.
Hematology
. 2023 Feb;
28(1):2178997.
PMID: 36803194
Objectives: To describe the incorporation of monoclonal antibodies (mAb) in real-world (RW) practice for the treatment of patients with relapsed refractory multiple myeloma (RRMM) in a setting with other treatment...
4.
Termini R, Zihala D, Terpos E, Perez-Montana A, Jelinek T, Raab M, et al.
Clin Cancer Res
. 2022 Sep;
28(21):4771-4781.
PMID: 36074126
Purpose: Early intervention in smoldering multiple myeloma (SMM) requires optimal risk stratification to avoid under- and overtreatment. We hypothesized that replacing bone marrow (BM) plasma cells (PC) for circulating tumor...
5.
Moreno D, Clapes V, Soler J, Gonzalez-Montes Y, Gironella M, Motllo C, et al.
Clin Lymphoma Myeloma Leuk
. 2022 May;
22(8):635-642.
PMID: 35610120
Introduction: Daratumumab is an anti-CD38 agent that was first investigated as single agent in GEN501 and SIRIUS trials in patients with advanced multiple myeloma (MM). Overall response rate (ORR) was...
6.
Ribera J, Morgades M, Genesca E, Chapchap E, Montesinos P, Acuna-Cruz E, et al.
Hematol Oncol
. 2021 Aug;
39(4):529-538.
PMID: 34405901
Despite high complete remission (CR) rates with frontline therapy, relapses are frequent in adults with T-cell acute lymphoblastic leukemia (T-ALL) with limited salvage options. We analyzed the outcomes and prognostic...
7.
Granell M, Senin A, Barata A, Cibeira M, Gironella M, Lopez-Pardo J, et al.
Bone Marrow Transplant
. 2021 Aug;
56(12):2904-2910.
PMID: 34404917
Return to work (RTW) is a marker of functional recovery in cancer patients, with quality of life, financial and social implications. We investigated frequency and factors associated with RTW in...
8.
Ribera J, Morgades M, Coll R, Barba P, Lopez-Lorenzo J, Montesinos P, et al.
Clin Lymphoma Myeloma Leuk
. 2021 Aug;
21(10):e801-e809.
PMID: 34376375
Background And Objective: SARS-CoV-2 infection has bimodal distribution in Europe with a first wave in March to June 2020 and a second in September 2020 to February 2021. We compared...
9.
Ribera J, Morgades M, Ciudad J, Montesinos P, Esteve J, Genesca E, et al.
Blood
. 2020 Nov;
137(14):1879-1894.
PMID: 33150388
The need for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adults with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) with high-risk (HR) features and adequate measurable residual disease (MRD) clearance...
10.
Ribera J, Garcia O, Chapchap E, Gil C, Gonzalez-Campos J, Barba P, et al.
Clin Lymphoma Myeloma Leuk
. 2020 Apr;
20(8):e513-e522.
PMID: 32336676
Background: The treatment of acute lymphoblastic leukemia (ALL) in older adults and elderly patients is a challenge, and modern protocols include targeted therapy and immunotherapy in combination with attenuated or...